Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Enzalutamide + Taselisib||Phase Ib/II||Actionable||In a Phase Ib/II trial, the combination of Taselisib (GDC-0032) and Xtandi (enzalutamide) resulted in a clinical benefit rate of 35.7% (5/14) in patients with triple-negative breast cancer, with partial response in one patient and stable disease in 4 patients, compared to no clinical benefit with Xtandi (enzalutamide) alone, and PIK3CA mutations and AR expression did not correlate with response (PMID: 31822498; NCT02457910).||31822498|